Janux Therapeutics (NASDAQ:JANX) Rating Reiterated by Cantor Fitzgerald

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $100.00 target price on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 102.18% from the company’s previous close.

Several other equities analysts have also commented on JANX. HC Wainwright reiterated a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. Wedbush reissued an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Finally, Stifel Nicolaus started coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $66.13.

Janux Therapeutics Trading Down 0.9 %

JANX stock opened at $49.46 on Monday. The firm has a 50-day moving average of $43.14 and a two-hundred day moving average of $44.16. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -40.54 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. The firm’s revenue was up 709.1% on a year-over-year basis. As a group, equities analysts forecast that Janux Therapeutics will post -1.18 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00. Following the transaction, the insider now owns 2,959,175 shares in the company, valued at $139,081,225. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 268,578 shares of company stock worth $12,071,151 in the last quarter. 35.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Summit Securities Group LLC acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth approximately $29,000. Amalgamated Bank increased its holdings in Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after buying an additional 368 shares during the period. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics in the 2nd quarter valued at $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Janux Therapeutics during the 2nd quarter worth about $151,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Janux Therapeutics during the 2nd quarter valued at about $215,000. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.